Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2Business Wire • 02/18/22
Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda's Plasma-Derived Therapies Business UnitBusiness Wire • 02/15/22
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/03/22
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong MomentumBusiness Wire • 02/03/22
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)Business Wire • 01/31/22
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/10/22
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid TumorsBusiness Wire • 01/10/22
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional StudyBenzinga • 12/22/21
Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic PouchitisBusiness Wire • 12/17/21
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021Business Wire • 12/13/21
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)Business Wire • 12/08/21
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual MeetingBusiness Wire • 12/07/21
Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United StatesBusiness Wire • 12/02/21